Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 2.41
UTHR's Cash to Debt is ranked higher than
63% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. UTHR: 2.41 )
UTHR' s 10-Year Cash to Debt Range
Min: 0.91   Max: 5455.83
Current: 2.41

0.91
5455.83
Equity to Asset 0.60
UTHR's Equity to Asset is ranked higher than
67% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. UTHR: 0.60 )
UTHR' s 10-Year Equity to Asset Range
Min: 0.43   Max: 0.94
Current: 0.6

0.43
0.94
Interest Coverage 16.20
UTHR's Interest Coverage is ranked higher than
53% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. UTHR: 16.20 )
UTHR' s 10-Year Interest Coverage Range
Min: 2.02   Max: 3302.25
Current: 16.2

2.02
3302.25
F-Score: 6
Z-Score: 4.96
M-Score: -3.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 26.19
UTHR's Operating margin (%) is ranked higher than
94% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. UTHR: 26.19 )
UTHR' s 10-Year Operating margin (%) Range
Min: -24714.81   Max: 46.03
Current: 26.19

-24714.81
46.03
Net-margin (%) 15.63
UTHR's Net-margin (%) is ranked higher than
90% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. UTHR: 15.63 )
UTHR' s 10-Year Net-margin (%) Range
Min: -23703.7   Max: 56.09
Current: 15.63

-23703.7
56.09
ROE (%) 13.86
UTHR's ROE (%) is ranked higher than
92% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. UTHR: 13.86 )
UTHR' s 10-Year ROE (%) Range
Min: -76.65   Max: 36.15
Current: 13.86

-76.65
36.15
ROA (%) 8.36
UTHR's ROA (%) is ranked higher than
92% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. UTHR: 8.36 )
UTHR' s 10-Year ROA (%) Range
Min: -68.45   Max: 22.31
Current: 8.36

-68.45
22.31
ROC (Joel Greenblatt) (%) 62.91
UTHR's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. UTHR: 62.91 )
UTHR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1372.3   Max: 90.19
Current: 62.91

-1372.3
90.19
Revenue Growth (%) 28.20
UTHR's Revenue Growth (%) is ranked higher than
92% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. UTHR: 28.20 )
UTHR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 231.7
Current: 28.2

0
231.7
EBITDA Growth (%) 24.00
UTHR's EBITDA Growth (%) is ranked higher than
94% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. UTHR: 24.00 )
UTHR' s 10-Year EBITDA Growth (%) Range
Min: -56   Max: 127.7
Current: 24

-56
127.7
EPS Growth (%) 20.60
UTHR's EPS Growth (%) is ranked higher than
92% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. UTHR: 20.60 )
UTHR' s 10-Year EPS Growth (%) Range
Min: -50.4   Max: 153.6
Current: 20.6

-50.4
153.6
» UTHR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

UTHR Guru Trades in Q1 2013

Jim Simons 323,175 sh (New)
Paul Tudor Jones 16,700 sh (+9.87%)
Joel Greenblatt 295,921 sh (+2.24%)
Steven Cohen Sold Out
David Dreman 55,625 sh (-2.46%)
John Hussman 468,000 sh (-6.4%)
Vanguard Health Care Fund 1,320,000 sh (-11.23%)
» More
Q2 2013

UTHR Guru Trades in Q2 2013

Jim Simons 590,378 sh (+82.68%)
Joel Greenblatt 341,330 sh (+15.34%)
Vanguard Health Care Fund 1,320,000 sh (unchged)
John Hussman 468,000 sh (unchged)
David Dreman 53,200 sh (-4.36%)
Paul Tudor Jones 15,600 sh (-6.59%)
» More
Q3 2013

UTHR Guru Trades in Q3 2013

Joel Greenblatt 372,147 sh (+9.03%)
Vanguard Health Care Fund Sold Out
David Dreman Sold Out
John Hussman 358,000 sh (-23.5%)
Jim Simons 440,778 sh (-25.34%)
Paul Tudor Jones 7,700 sh (-50.64%)
» More
Q4 2013

UTHR Guru Trades in Q4 2013

Steven Cohen 24,174 sh (New)
Paul Tudor Jones 5,100 sh (-33.77%)
Joel Greenblatt 194,595 sh (-47.71%)
Jim Simons 224,278 sh (-49.12%)
John Hussman 134,000 sh (-62.57%)
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-12-31 Reduce -62.57%1%$80.03 - $114.51 $ 96.27%134000
Joel Greenblatt 2013-12-31 Reduce -47.71%0.45%$80.03 - $114.51 $ 96.27%194595
John Hussman 2013-09-30 Reduce -23.5%0.33%$66.1 - $79.58 $ 96.232%358000
Vanguard Health Care Fund 2013-09-30 Sold Out 0.32%$66.1 - $79.58 $ 96.232%0
David Dreman 2013-09-30 Sold Out 0.12%$66.1 - $79.58 $ 96.232%0
Joel Greenblatt 2013-06-30 Add 15.34%0.13%$59.64 - $69.31 $ 96.249%341330
David Dreman 2012-12-31 New Buy0.09%$44.99 - $58.91 $ 96.285%57025
John Hussman 2012-09-30 New Buy0.67%$49.73 - $58.2 $ 96.278%500000
Joel Greenblatt 2012-06-30 Add 101.59%0.6%$41.19 - $49.51 $ 96.2118%332744
Richard Perry 2012-06-30 Sold Out 0.04%$41.19 - $49.51 $ 96.2118%0
Joel Greenblatt 2012-03-31 Add 82.68%0.31%$45.54 - $50.99 $ 96.2113%165063
Richard Perry 2012-03-31 New Buy0.04%$45.54 - $50.99 $ 96.2113%15300
Joel Greenblatt 2011-12-31 Add 38.75%0.15%$37.21 - $47.54 $ 96.2131%90355
Joel Greenblatt 2011-09-30 Add 274.82%0.29%$37.47 - $57.38 $ 96.298%65122
Vanguard Health Care Fund 2011-09-30 Add 77.9%0.16%$37.47 - $57.38 $ 96.298%1787000
Michael Price 2011-09-30 Sold Out 0.1%$37.47 - $57.38 $ 96.298%0
George Soros 2011-09-30 Sold Out 0.0776%$37.47 - $57.38 $ 96.298%0
Michael Price 2011-06-30 Reduce -82.59%0.59%$53.49 - $70.7 $ 96.252%12500
Vanguard Health Care Fund 2011-06-30 Add 183.36%0.18%$53.49 - $70.7 $ 96.252%1004500
Joel Greenblatt 2011-06-30 New Buy0.13%$53.49 - $70.7 $ 96.252%17374
Michael Price 2011-03-31 Reduce -24.97%0.24%$63.22 - $69.54 $ 96.244%71800
George Soros 2011-03-31 Add 1213.41%0.08%$63.22 - $69.54 $ 96.244%107700
Joel Greenblatt 2011-03-31 Sold Out $63.22 - $69.54 $ 96.244%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about United Therapeutics Corporation

High-Dollar Insider Sells - Zuckerberg Sells 41M Facebook Shares
Yesterday insider executives made large sells at Facebook Inc. (FB), United Therapeutics Corporation (UTHR) and Hillenbrand Inc. (HI), all companies held by billionaires. Here are the company updates and trade highlights. Read more...
Vanguard Health Care Fund Selling Update
The updated portfolio of the Vanguard Health Care Fund lists 92 stocks, four of them new, a total value at $29.45 billion, and a quarter-over-quarter turnover of 4%. The portfolio is weighted with two sectors: health care at 91.5% and consumer defensive at 2.9%. Vanguard Health Care Fund has averaged a return of 24.96% over 12 months and 9.5% over 10 years, according to the GuruFocus Score Board of Gurus. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 30.20
UTHR's P/E(ttm) is ranked higher than
67% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 28.60 vs. UTHR: 30.20 )
UTHR' s 10-Year P/E(ttm) Range
Min: 8.83   Max: 218.78
Current: 30.2

8.83
218.78
P/B 4.10
UTHR's P/B is ranked higher than
69% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. UTHR: 4.10 )
UTHR' s 10-Year P/B Range
Min: 2.01   Max: 10.39
Current: 4.1

2.01
10.39
P/S 4.70
UTHR's P/S is ranked higher than
75% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. UTHR: 4.70 )
UTHR' s 10-Year P/S Range
Min: 2.83   Max: 18.02
Current: 4.7

2.83
18.02
PFCF 13.40
UTHR's PFCF is ranked higher than
88% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. UTHR: 13.40 )
UTHR' s 10-Year PFCF Range
Min: 9.7   Max: 666.33
Current: 13.4

9.7
666.33
EV-to-EBIT 16.70
UTHR's EV-to-EBIT is ranked higher than
67% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. UTHR: 16.70 )
UTHR' s 10-Year EV-to-EBIT Range
Min: 5.5   Max: 363.2
Current: 16.7

5.5
363.2
PEG 0.40
UTHR's PEG is ranked higher than
90% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. UTHR: 0.40 )
UTHR' s 10-Year PEG Range
Min: 0   Max: 5.09
Current: 0.4

0
5.09
Shiller P/E 42.60
UTHR's Shiller P/E is ranked higher than
64% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.74 vs. UTHR: 42.60 )
UTHR' s 10-Year Shiller P/E Range
Min: 25   Max: 129.35
Current: 42.6

25
129.35

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 4.00
UTHR's Price/Tangible Book is ranked higher than
73% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. UTHR: 4.00 )
UTHR' s 10-Year Price/Tangible Book Range
Min: 1.16   Max: 14.47
Current: 4

1.16
14.47
Price/DCF (Projected) 1.80
UTHR's Price/DCF (Projected) is ranked higher than
82% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. UTHR: 1.80 )
UTHR' s 10-Year Price/DCF (Projected) Range
Min: 1.37   Max: 24.34
Current: 1.8

1.37
24.34
Price/Median PS Value 0.60
UTHR's Price/Median PS Value is ranked higher than
86% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. UTHR: 0.60 )
UTHR' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 287.5
Current: 0.6

0.4
287.5
Price/Graham Number 2.20
UTHR's Price/Graham Number is ranked higher than
70% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. UTHR: 2.20 )
UTHR' s 10-Year Price/Graham Number Range
Min: 0.99   Max: 5.79
Current: 2.2

0.99
5.79
Earnings Yield (Greenblatt) 6.00
UTHR's Earnings Yield (Greenblatt) is ranked higher than
71% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. UTHR: 6.00 )
UTHR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 18
Current: 6

0.3
18
Forward Rate of Return (Yacktman) 1.30
UTHR's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. UTHR: 1.30 )
UTHR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.7   Max: 1.7
Current: 1.3

-4.7
1.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:UTH.Germany
United Therapeutics Corporation was incorporated in Delaware in June 1996. The Company is a biotechnology company, which is focused on the development and commercialization of products to address the medical needs of patients with chronic and life-threatening conditions. The Company operates two business segments: pharmaceuticals and telemedicine. The pharmaceutical segment includes all activities associated with the research, development, manufacturing and commercialization of its therapeutic products. The telemedicine segment includes all activities associated with the development and manufacturing of patient cardiac monitoring products and services. Its therapeutic products and product candidates include: Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Monoclonal Antibodies (MAbs),Glycobiology Antiviral Agents, and Cell-Based Therapy. Prostacyclin analogues are stable synthetic forms of prostacyclin, an important molecule produced by the body that has powerful effects on blood vessel health and function. Its product Remodulin (treprostinil) Injection (Remodulin) to be administered subcutaneously or intravenously for the treatment of pulmonary arterial hypertension (PAH). PDE-5 inhibitors act to inhibit the degradation of cyclic guanosine monophosphate (cGMP) in cells. cGMP is activated by nitric oxide (NO) to effect relaxation of vascular smooth muscle. Its PDE-5 inhibitor product is Adcirca (tadalafil) tablets (Adcirca), a once-daily oral therapy for the treatment of PAH. MAbs act by targeting tumor-associated antigens on cancer cells to activate a patient's immune system against the cancer cells. The Company is developing the antibody Ch14.18 MAb for the treatment of neuroblastoma, under an agreement with the National Cancer Institute. Glycobiology antiviral agents are a novel class of small, sugar-like molecules that have shown pre-clinical indications of efficacy against a broad range of viruses. The Company generates revenues mainly from the sale of Remodulin, Tyvaso and Adcirca. The Company competes with the developers, manufacturers and distributors of all of these products for customers, funding, access to licenses, personnel, third-party collaborators, product development and commercialization.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide